F-Fluoromisonidazole in Tumor Hypoxia Imaging

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Dec 8

PMID 29212283

Citations 31

Authors

Zuoyu Xu

Xiao-Feng Li

Hongyan Zou

Xilin Sun

Baozhong Shen

Affiliations

Soon will be listed here.

Abstract

Hypoxia is a common feature of solid tumors that is closely associated with radiotherapy and chemotherapy resistance, metastasis and tumors prognosis. Thus, it is important to assess hypoxia in tumors for estimating prognosis and selecting appropriate treatment procedures. F-Fluoromisonidazole positron emission tomography (F-FMISO PET) has been widely used to visualize tumor hypoxia in a comprehensive and noninvasive way, both in the clinical and preclinical settings. Here we review the concept, mechanisms and detection methods of tumor hypoxia. Furthermore, we discuss the correlation between F-FMISO PET and other detection methods, current applications of F-FMISO PET and the development prospects of this imaging technology.

Citing Articles

Defining hypoxia in cancer: A landmark evaluation of hypoxia gene expression signatures.

Di Giovannantonio M, Hartley F, Elshenawy B, Barberis A, Hudson D, Shafique H Cell Genom. 2025; 5(2):100764.

PMID: 39892389 PMC: 11872601. DOI: 10.1016/j.xgen.2025.100764.

Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.

Glaviano A, Lau H, Carter L, Lee E, Lam H, Okina E J Hematol Oncol. 2025; 18(1):6.

PMID: 39806516 PMC: 11733683. DOI: 10.1186/s13045-024-01634-6.

Emerging Radiopharmaceuticals in Pet Imaging for Mesothelioma: A Review of [F]FDG Alternatives.

Guglielmo P, Crivellaro C, Castello A, Della Corte C, Pagano M, Marchesi S Mol Diagn Ther. 2024; 29(1):55-66.

PMID: 39514167 DOI: 10.1007/s40291-024-00756-4.

PET radiomics in lung cancer: advances and translational challenges.

Zhang Y, Huang W, Jiao H, Kang L EJNMMI Phys. 2024; 11(1):81.

PMID: 39361110 PMC: 11450131. DOI: 10.1186/s40658-024-00685-5.

Data Science Opportunities To Improve Radiotherapy Planning and Clinical Decision Making.

Deasy J Semin Radiat Oncol. 2024; 34(4):379-394.

PMID: 39271273 PMC: 11698470. DOI: 10.1016/j.semradonc.2024.07.012.

References

Gagel B, Reinartz P, Dimartino E, Zimny M, Pinkawa M, Maneschi P . pO(2) Polarography versus positron emission tomography ([(18)F] fluoromisonidazole, [(18)F]-2-fluoro-2'-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia. Strahlenther Onkol. 2004; 180(10):616-22. DOI: 10.1007/s00066-004-1229-y. View

Colombie M, Gouard S, Frindel M, Vidal A, Cherel M, Kraeber-Bodere F . Focus on the Controversial Aspects of (64)Cu-ATSM in Tumoral Hypoxia Mapping by PET Imaging. Front Med (Lausanne). 2015; 2:58. PMC: 4547458. DOI: 10.3389/fmed.2015.00058. View

Maftei C, Shi K, Bayer C, Astner S, Vaupel P . Comparison of (immuno-)fluorescence data with serial [¹⁸F]Fmiso PET/CT imaging for assessment of chronic and acute hypoxia in head and neck cancers. Radiother Oncol. 2011; 99(3):412-7. DOI: 10.1016/j.radonc.2011.05.079. View

Piert M, Machulla H, Picchio M, Reischl G, Ziegler S, Kumar P . Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med. 2005; 46(1):106-13. View

Jewell U, Kvietikova I, Scheid A, Bauer C, Wenger R, Gassmann M . Induction of HIF-1alpha in response to hypoxia is instantaneous. FASEB J. 2001; 15(7):1312-4. View

Stroka D, Burkhardt T, Desbaillets I, Wenger R, Neil D, Bauer C . HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J. 2001; 15(13):2445-53. DOI: 10.1096/fj.01-0125com. View

Warren D, Partridge M . The role of necrosis, acute hypoxia and chronic hypoxia in F-FMISO PET image contrast: a computational modelling study. Phys Med Biol. 2016; 61(24):8596-8624. PMC: 5717515. DOI: 10.1088/1361-6560/61/24/8596. View

Ren Y, Hao P, Dutta B, Cheow E, Sim K, Gan C . Hypoxia modulates A431 cellular pathways association to tumor radioresistance and enhanced migration revealed by comprehensive proteomic and functional studies. Mol Cell Proteomics. 2012; 12(2):485-98. PMC: 3567868. DOI: 10.1074/mcp.M112.018325. View

Tsai Y, Wu K . Hypoxia-regulated target genes implicated in tumor metastasis. J Biomed Sci. 2012; 19:102. PMC: 3541338. DOI: 10.1186/1423-0127-19-102. View

10.

Okamoto S, Shiga T, Yasuda K, Ito Y, Magota K, Kasai K . High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer. J Nucl Med. 2013; 54(2):201-7. DOI: 10.2967/jnumed.112.109330. View

11.

Sadick M, Schoenberg S, Hoermann K, Sadick H . Current oncologic concepts and emerging techniques for imaging of head and neck squamous cell cancer. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2013; 11:Doc08. PMC: 3544205. DOI: 10.3205/cto000090. View

12.

Norikane T, Yamamoto Y, Maeda Y, Kudomi N, Matsunaga T, Haba R . Correlation of (18)F-fluoromisonidazole PET findings with HIF-1α and p53 expressions in head and neck cancer: comparison with (18)F-FDG PET. Nucl Med Commun. 2013; 35(1):30-5. DOI: 10.1097/MNM.0000000000000010. View

13.

Dery M, Michaud M, Richard D . Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. Int J Biochem Cell Biol. 2004; 37(3):535-40. DOI: 10.1016/j.biocel.2004.08.012. View

14.

Lehtio K, Oikonen V, Nyman S, Gronroos T, Roivainen A, Eskola O . Quantifying tumour hypoxia with fluorine-18 fluoroerythronitroimidazole ([18F]FETNIM) and PET using the tumour to plasma ratio. Eur J Nucl Med Mol Imaging. 2002; 30(1):101-8. DOI: 10.1007/s00259-002-1016-x. View

15.

Sato J, Kitagawa Y, Yamazaki Y, Hata H, Okamoto S, Shiga T . 18F-fluoromisonidazole PET uptake is correlated with hypoxia-inducible factor-1α expression in oral squamous cell carcinoma. J Nucl Med. 2013; 54(7):1060-5. DOI: 10.2967/jnumed.112.114355. View

16.

Hugonnet F, Fournier L, Medioni J, Smadja C, Hindie E, Huchet V . Metastatic renal cell carcinoma: relationship between initial metastasis hypoxia, change after 1 month's sunitinib, and therapeutic response: an 18F-fluoromisonidazole PET/CT study. J Nucl Med. 2011; 52(7):1048-55. DOI: 10.2967/jnumed.110.084517. View

17.

Cardenas-Navia L, Richardson R, Dewhirst M . Targeting the molecular effects of a hypoxic tumor microenvironment. Front Biosci. 2007; 12:4061-78. DOI: 10.2741/2372. View

18.

Carlin S, Humm J . PET of hypoxia: current and future perspectives. J Nucl Med. 2012; 53(8):1171-4. DOI: 10.2967/jnumed.111.099770. View

19.

Lim J, Berridge M . An efficient radiosynthesis of [18F]fluoromisonidazole. Appl Radiat Isot. 1993; 44(8):1085-91. DOI: 10.1016/0969-8043(93)90110-v. View

20.

Kurihara H, Honda N, Kono Y, Arai Y . Radiolabelled agents for PET imaging of tumor hypoxia. Curr Med Chem. 2012; 19(20):3282-9. DOI: 10.2174/092986712801215964. View